This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Mar 2012

Argen-X Launches NHance Technology

Argen-X has launched its latest technology for creating human antibody therapeutics.

Dutch biopharmaceutical firm Argen-X has launched its latest technology for creating human antibody therapeutics.

 

The firm says NHance prolongs the circulation time of therapeutic antibodies in the human body by engineering of the antibody constant region (Fc). It is said to provide reduced antibody dosing, increased efficacy and improved overall convenience to the patient.

 

The new tech is based on proprietary Fc region mutations and was invented by Dr Sally Ward, Professor of Immunology at the University of Texas Southwestern Medical Center. Argen-X has acquired an exclusive global licence to the technology.

 

Argen-X will apply the NHance technology to its partners’ antibody discovery pro

Related News